Influence of preformed donor-specific antibodies and C4d on early liver allograft function

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 12, 2013, Pages 1444-1451

  Perera, M T ^a,c   Silva, M A ^a   Murphy, N ^a   Briggs, D ^d   Mirza, D F ^a   Neil, D A H ^b  

^a Liver Unit   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Alloimmunity; Human leukocyte antigen; Humoral rejection; Liver transplantation; Positive cross match

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY MEDIATED REJECTION; ARTICLE; BRAIN DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRYOPRESERVATION; DISEASE SEVERITY; DONOR; FATTY LIVER; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT RECIPIENT; HEART DEATH; HUMAN; LIVER BIOPSY; LIVER CELL; LIVER FUNCTION; LIVER GRAFT; LIVER TRANSPLANTATION; MIDDLE AGED; PRESERVATION; PRIORITY JOURNAL; REPERFUSION INJURY;

AGED; ALLOGRAFTS; BIOLOGICAL MARKERS; BIOPSY; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDE FRAGMENTS; PRIMARY GRAFT DYSFUNCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84892175339     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.845795     Document Type: Article

References (34)

1. Andres GA, Ansell ID, Halgrimson CG, Hsu KC, Porter KA, Starzl TE, et al. Immunopathological studies of orthotopic human liver allografts. Lancet 1972;1:275-80
2. Starzl TE, Ishikawa M, Putnam CW, Porter KA, Picache R, Husberg BS, et al. Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc 1974;6:129-39
3. Rowshani AT, Bemelman FJ, Lardy NM, Ten Berge IJ. Humoral immunity in renal transplantation: Clinical significance and therapeutic approach. Clin Transplant 2008;22: 689-99
4. Masson E, Stern M, Chabod J, Thevenin C, Gonin F, Rebibou JM, et al. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies. J Heart Lung Transplant 2007;26:642-5
5. Demetris AJ, Jaffe R, Tzakis A, Ramsey G, Todo S, Belle S, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988;132:489-502
6. Demetris AJ, Jaffe R, Tzakis A, Ramsey G, Todo S, Belle S, et al. Antibody mediated rejection of human liver allografts: Transplantation across ABO blood group barriers. Transplant Proc 1989;21:2217-20
7. Demetris AJ, Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992;16:671-81
8. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003;3:665-73
9. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005;5:807-17
10. Colvin RB. Pathology of chronic humoral rejection. Contrib Nephrol 2009;162:75-86
11. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007;18: 1046-56
12. Rostron A, Carter V, Mutunga M, Cavanagh G, O'Suilleabhain C, Burt A, et al. A case of acute humoral rejection in liver transplantation: Successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int 2005;18:1298-301
13. Watson R, Kozlowski T, Nickeleit V, Woosley JT, Schmitz JL, Zacks SL, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006;6:3022-9
14. Hadaya K, Ferrari-Lacraz S, Giostra E, Majno P, Moll S, Rubbia-Brandt L, et al. Humoral and cellular rejection after combined liver-kidney transplantation in low immunologic risk recipients. Transpl Int 2009;22:242-6
15. Wilson CH, Agarwal K, Carter V, Burt AD, Hubscher S, Talbot D, et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006;82:988-9
16. Ratner LE, Phelan D, Brunt EM, Mohanakumar T, Hanto DW. Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation 1993;55:814-19
17. Troxell ML,Weintraub LA, Higgins JP, Kambham N. Comparison of C4d immunostaining methods in renal allograft biopsies. Clin J Am Soc Nephrol 2006;1:583-91
18. Troxell ML, Higgins JP, Kambham N. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006;130:1489-96
19. Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation 2002;74:711-17
20. Haas M, Mirocha J. Early ultrastructural changes in renal allografts: Correlation with antibody-mediated rejection and transplant glomerulopathy. AmJ Transplant 2011;11:2123-31
21. Silva MA, Mirza DF, Murphy N, Richards DA, Reynolds GM, Wigmore SJ, et al. Intrahepatic complement activation, sinusoidal endothelial injury, and lactic acidosis are associated with initial poor function of the liver after transplantation. Transplantation 2008;85:718-25
22. Neil DA, Hubscher SG. Current views on rejection pathology in liver transplantation. Transpl Int 2010;23:971-83
23. Bellamy CO. Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: Applications and pitfalls. Liver Transpl 2011;17:747-50
24. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007;50:739-49
25. Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012;12:1504-10
26. Hathaway M, Gunson BK, Keogh AC, Briggs D, McMaster P, Neuberger JM. A positive crossmatch in liver transplantation-no effect or inappropriate analysis? A prospective study. Transplantation 1997;64:54-9
27. Lobo PI, Spencer C, Douglas MT, Stevenson WC, Pruett TL. The lack of long-term detrimental effects on liver allografts caused by donor-specific anti-HLA antibodies. Transplantation 1993;55:1063-6
28. Neumann UP, Lang M, Moldenhauer A, Langrehr JM, Glanemann M, Kahl A, et al. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation 2001;71:1163-8
29. Takaya S, Bronsther O, Iwaki Y, Nakamura K, Abu- Elmagd K, Yagihashi A, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992;53:400-6
30. Castillo-Rama M, Castro MJ, Bernardo I, Meneu-Diaz JC, Elola-Olaso AM, Calleja-Antolin SM, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008;14:554-62
31. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011;17:357-68
32. O'Leary JG, Kaneku H, Jennings LW, Banuelos N, Susskind BM, Terasaki PI, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013;19:973-80
33. BattsKP,Moore SB, Perkins JD,WiesnerRH,GrambschPM, Krom RA. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988;45:376-9
34. Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V. Sinusoidal C4d deposits in liver allografts indicate an antibodymediated response: Diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012;18:641-58